Associated tags: Inflammation, Acute myeloid leukemia, Cancer, Science, MD, Chemistry, AML, Carbohydrate, Health, Biotechnology, Oncology, Glycomimetic, Clinical Trials, Research, Pharmaceutical, Pharmaceutical industry, Patient
Locations: NEW YORK, CHINA, NY, AUSTRALIA, TX, NEW ZEALAND, UNITED STATES, NORTH AMERICA, MASSACHUSETTS, MARYLAND, MA
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m.
- To access the call by phone, please go to this registration link and you will be provided with dial in details.
- Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
- A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.
Retrieved on:
Wednesday, March 27, 2024
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Research,
NCI,
Sickle cell disease,
Plasma,
ASH,
Disease,
AML,
Patient,
National Cancer Institute,
NDA,
Inflammation,
Volunteering,
Cancer,
VOE,
Pharmacokinetics,
SCD,
Therapy,
Data,
FDA,
Engineering,
Pharmaceutical industry GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023.
- In August 2023, GlycoMimetics initiated a Phase 1a single-center, double-blind, randomized, placebo-controlled, sequential, single ascending dose trial in healthy adult volunteers.
- R&D Expenses: The company’s research and development expenses decreased to $5.3 million for the quarter ended December 31, 2023, compared to $5.9 million for the fourth quarter of 2022.
- G&A Expenses: The company’s general and administrative expenses decreased to $4.3 million for the quarter ended December 31, 2023, compared to $4.7 million for the fourth quarter of 2022.
Retrieved on:
Wednesday, March 13, 2024
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The Company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates. The Company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m.
- To access the call by phone, please go to this registration link and you will be provided with dial in details.
- Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
- A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.
Retrieved on:
Monday, February 26, 2024
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The Company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates. The Company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m.
- ET.
- A live webcast of the panel presentation will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations .
- An archived recording will be available for 30 days following the event.
Retrieved on:
Monday, February 12, 2024
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The Company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates. The Company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Key Points:
- GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 6, 2024 of a non-qualified stock option award to purchase an aggregate of 130,000 shares of the Company’s common stock to Shantha Tyavanagimatt, Ph.D., the Company’s new Senior Vice President, Technical Operations.
- The award was granted as an inducement equity award outside of the Company’s Amended and Restated 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4) and was made as an inducement material to the acceptance of employment with the Company by the new employee.
- The option grant has an exercise price of $3.20 per share, the closing price of the Common Stock on the date of grant and is subject to the terms and conditions of a stock option agreement and the GlycoMimetics, Inc.
- Amended and Restated Inducement Plan, which provides for the granting of stock options and other equity awards to new employees.
Retrieved on:
Thursday, January 4, 2024
Biotechnology,
FDA,
Health,
Pharmaceutical,
Clinical Trials,
Pharmacokinetics,
Plasma,
Safety,
Sickle cell disease,
Inflammation,
Volunteering,
Cancer,
Pharmaceutical industry GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced positive initial safety, tolerability, and pharmacokinetic results from a Phase 1a study of GMI-1687 in healthy volunteers.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced positive initial safety, tolerability, and pharmacokinetic results from a Phase 1a study of GMI-1687 in healthy volunteers.
- “Our Phase 1a data confirm this highly potent, second-generation E-selectin antagonist has an excellent profile for further development, with no dose-limiting toxicities or safety signals observed along with linear pharmacokinetics.
- Subcutaneous dosing achieved target therapeutic plasma concentration and linear pharmacokinetics with rapid renal clearance across all dosing levels.
- Analysis of data is ongoing with full results expected to be presented at an upcoming medical conference.
Retrieved on:
Sunday, December 10, 2023
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Acute myeloid leukemia,
LDAC,
Safety,
National Cancer Institute,
ASH,
Leukemia,
Cellular,
IIT,
Cytogenetics,
HCT,
Pedal,
Patient,
Inflammation,
Male,
Cytarabine,
Biobank,
University,
Transplant,
AML,
MD Anderson Cancer Center,
Cancer,
Society,
Myelodysplastic syndrome,
Cladribine,
Haematopoietic system,
Venetoclax,
Pharmaceutical industry,
Glycomimetic “These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.
Key Points:
- “These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.
- Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
This Phase 1b/2 clinical trial evaluated safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and LDAC in patients with ts-AML.
- This rare, high-risk study population is defined by prior chemotherapy treatment of a previous hematologic disorder, such as myelodysplastic syndrome.
- Study investigators concluded these data support this low-risk approach to marrow blast reduction and disease control in preparation for HCT.
Retrieved on:
Thursday, November 9, 2023
Research,
FDA,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
Conference,
Online shopping,
Cryptocurrency,
Glycomimetic GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m.
- ET.
- A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations .
- An archived recording will be available for 30 days following the event.
Research,
FDA,
Clinical Trials,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
MD Anderson Cancer Center,
Neurotransmission,
NCI,
Food,
Cytarabine,
Alliance for Clinical Trials in Oncology,
Inflammation,
Safety,
European Medicines Agency,
Sickle cell disease,
Volunteering,
ASH,
Pharmacokinetics,
Cancer,
National Cancer Institute,
PIP,
NDA,
Cladribine,
Patient,
Food and Drug Administration,
AML,
D,
Pharmaceutical industry,
Glycomimetic GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
- With the addition of the time-based analysis, the company expects topline results by the end of Q2 2024.
- Third Quarter 2023 Financial Results:
Cash position: As of September 30, 2023, GlycoMimetics had cash and cash equivalents of $49.4 million as compared to $47.9 million as of December 31, 2022.
- A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates with the goal of developing transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
Key Points:
- GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m.
- To access the call by phone, please go to this registration link and you will be provided with dial in details.
- Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
- A live webcast of the call will be available on the “ Investors ” tab on the GlycoMimetics website.
